Prescription medicine
Mometasone and olopatadine Brand names: Ryaltris
Mometasone and olopatadine (Ryaltris) is a prescription medicine with an FDA approval on record since 2022. No generic is listed; pharmacies paid $7.67 per gram (Ryaltris 665-25 mcg spray) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the mometasone and olopatadine FDA label on DailyMed (effective July 21, 2026, Glenmark Pharmaceuticals Inc., USA); the NDA 211746 record on Drugs@FDA; every mometasone and olopatadine label on DailyMed.
Highlights of the record
FDA label of July 21, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageRYALTRIS is indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients of age 6 years and older.
Forms and strengths
Spray (metered).
On the market
- Earliest approval on file
- January 13, 2022 Ryaltris, Glenmark Speclt; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- November 21, 2044 Ryaltris spray; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $7.67 per gram Ryaltris 665-25 mcg spray
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2024 0 Class I among all firms' recalls; latest September 24, 2024
- FAERS reports
- 1,989 through July 30, 2026
What is mometasone and olopatadine used for?
From the label: indications and usageRYALTRIS is indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients of age 6 years and older. RYALTRIS is a combination of olopatadine, a histamine-1 (H1)-receptor inhibitor, and mometasone furoate, a corticosteroid, indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older.
Conditions named in the indications of mometasone and olopatadine's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Corticosteroid, Histamine-1 Receptor Antagonist, Histamine-1 Receptor Inhibitor and Mast Cell Stabilizer.
Source: FDA drug label (Ryaltris), Glenmark Pharmaceuticals Inc., USA, effective July 21, 2026 (SPL set 406be932-f00e-4c66-9dd1-c142090fe822), via openFDA; the full label on DailyMed
What does the patient leaflet for mometasone and olopatadine say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What should I avoid while using RYALTRIS?RYALTRIS can cause sleepiness or drowsiness. Do not drive, operate machinery, or do anything that needs you to be alert until you know how RYALTRIS affects you. • Do not drink alcohol or take any other medicines that may cause you to feel sleepy while using RYALTRIS.
From the patient leaflet: How should I store RYALTRIS?Store RYALTRIS upright with the purple dust cap on at room temperature between 68°F to 77°F (20°C to 25°C). • Do not freeze or refrigerate. • Safely throw away medicine that is out of date or no longer needed. • Throw away your RYALTRIS 240 metered sprays bottle after using 240 sprays after the first priming. Even though the bottle may not be completely empty, you may not get the correct dose of medicine if you continue to use it. Keep RYALTRIS and all medicines out of reach of children.
Source: FDA drug label (Ryaltris), Glenmark Pharmaceuticals Inc., USA, effective July 21, 2026 (SPL set 406be932-f00e-4c66-9dd1-c142090fe822), via openFDA; the full label on DailyMed
Is there a generic for mometasone and olopatadine (Ryaltris)?
No generic mometasone and olopatadine is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 17 patents for Ryaltris spray: the compound patent runs to April 8, 2039, and the last listed entry to November 21, 2044. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2022 earliest approval on file
- 2044 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for mometasone and olopatadine (Ryaltris)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $7.67 per gram (Ryaltris 665-25 mcg spray), down 7% from $8.22 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Ryaltris 665-25 mcg spray (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ryaltris 665-25 mcg spray | Brand | $7.67 per gram | n/a | -7% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has mometasone and olopatadine been recalled?
The FDA's Enforcement Report lists 1 recall naming mometasone and olopatadine since 2024: 0 Class I (the most serious), 1 Class II, 0 Class III; 1 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| September 24, 2024 | Class II | Glenmark Pharmaceuticals Inc., USA | Defective Delivery System: The dip tube is clogged causing the spray not to work. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What do FAERS reports show for mometasone and olopatadine?
The FDA Adverse Event Reporting System holds 1,989 reports that list mometasone and olopatadine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 12 are coded as a death and 78 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as mometasone and olopatadine?
7 other medicines are given the same way (nasal) and in the same FDA class as mometasone and olopatadine or labeled mainly for the same use (allergies), the same class first. Allergies lists all 36 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (nasal) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Fluticasone | Allergies | 67 labelers | $0.676 per gram 50 mcg spray | No current entry |
| Triamcinolone | Allergies | 24 labelers | $0.739 per mL 55 mcg nasal spr | Listed; available |
| Azelastine | Allergies | 16 labelers | $0.273 per mL 0.1% (137 mcg) spry | No current entry |
| Azelastine and fluticasone | Allergies | 4 labelers | $2.02 per gram 137-50 mcg spr | No current entry |
| Budesonide | Allergies | 5 labelers | $1.41 per mL 32 mcg nasal spray | No current entry |
| Beclomethasone | Allergies | none listed | $30.23 per gram 80 mcg nasal spray | No current entry |
| Cromolyn | Allergies | 2 labelers | n/a | Listed; available |
Every medicine labeled for the same conditions as mometasone and olopatadine
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to mometasone and olopatadine
- 7 medicines for the same use
- Other corticosteroids
- the pharmacologic class, with prices and generics
- Mometasone and olopatadine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other